Oncogene:毒蕈碱受体能够促进前列腺癌的去势抵抗性生长

2020-04-09 AlexYang MedSci原创

前列腺癌(PCa)神经支配能够导致PCa的恶化。然而,神经支配对PCa细胞的精细影响仍旧了解很少。

前列腺癌(PCa)神经支配能够导致PCa的恶化。然而,神经支配对PCa细胞的精细影响仍旧了解很少。

最近,有研究人员聚焦神经源性神经递质乙酰胆碱激活的毒蕈碱受体,展示了与其他类型的癌症相比,毒蕈碱受体1和3(m1和m3)在PCa临床样本中高表达,并且其相应的编码基因(CHRM1和CHRM3)的扩增或获得是PCa无进展生存较差的预后因素。更多的是,与激素敏感性PCa(HSPC)相比,m1和m3基因的获得或者扩增在去势抵抗性PCa(CRPC)中更为常见。另外,在HSPC来源的细胞中进行激素阻断来模仿去势和雄激素受体抑制时,m1和m3基因都表现出了异常的高表达。研究人员同时也展示了m1和m3信号的药理激活能够充分的诱导PCa细胞的去势抵抗性生长。同时,研究人员还发现m1和m3刺激能够通过FAK诱导YAP的激活,PTK2在CRPC中也经常性的扩增。FAK的药理抑制和YAP的敲除能够阻止m1和m3诱导的PCa细胞去势抵抗性生长。

最后,研究人员指出,他们的发现为毒蕈碱受体驱使的CRPC进展提供了新的治疗途径,即靶向FAK-YAP信号轴。

原始出处:

Yusuke Goto, Toshinori Ando, Hiroki Izumi et al. Muscarinic receptors promote castration-resistant growth of prostate cancer through a FAK-YAP signaling axis. Oncogene. 23 Mar 2020

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1770514, encodeId=f3021e7051415, content=<a href='/topic/show?id=05fe2665508' target=_blank style='color:#2F92EE;'>#体能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26655, encryptionId=05fe2665508, topicName=体能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80ae38174281, createdName=liubm568, createdTime=Sat May 23 16:12:17 CST 2020, time=2020-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666023, encodeId=a4291666023c0, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Sat Oct 31 05:12:17 CST 2020, time=2020-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049286, encodeId=318e204928654, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Wed Mar 17 15:12:17 CST 2021, time=2021-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558187, encodeId=3075155818ef1, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Sat Apr 11 04:12:17 CST 2020, time=2020-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040708, encodeId=26c71040e082b, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Apr 09 16:12:17 CST 2020, time=2020-04-09, status=1, ipAttribution=)]
    2020-05-23 liubm568
  2. [GetPortalCommentsPageByObjectIdResponse(id=1770514, encodeId=f3021e7051415, content=<a href='/topic/show?id=05fe2665508' target=_blank style='color:#2F92EE;'>#体能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26655, encryptionId=05fe2665508, topicName=体能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80ae38174281, createdName=liubm568, createdTime=Sat May 23 16:12:17 CST 2020, time=2020-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666023, encodeId=a4291666023c0, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Sat Oct 31 05:12:17 CST 2020, time=2020-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049286, encodeId=318e204928654, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Wed Mar 17 15:12:17 CST 2021, time=2021-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558187, encodeId=3075155818ef1, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Sat Apr 11 04:12:17 CST 2020, time=2020-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040708, encodeId=26c71040e082b, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Apr 09 16:12:17 CST 2020, time=2020-04-09, status=1, ipAttribution=)]
    2020-10-31 yige2012
  3. [GetPortalCommentsPageByObjectIdResponse(id=1770514, encodeId=f3021e7051415, content=<a href='/topic/show?id=05fe2665508' target=_blank style='color:#2F92EE;'>#体能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26655, encryptionId=05fe2665508, topicName=体能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80ae38174281, createdName=liubm568, createdTime=Sat May 23 16:12:17 CST 2020, time=2020-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666023, encodeId=a4291666023c0, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Sat Oct 31 05:12:17 CST 2020, time=2020-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049286, encodeId=318e204928654, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Wed Mar 17 15:12:17 CST 2021, time=2021-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558187, encodeId=3075155818ef1, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Sat Apr 11 04:12:17 CST 2020, time=2020-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040708, encodeId=26c71040e082b, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Apr 09 16:12:17 CST 2020, time=2020-04-09, status=1, ipAttribution=)]
    2021-03-17 cy0324
  4. [GetPortalCommentsPageByObjectIdResponse(id=1770514, encodeId=f3021e7051415, content=<a href='/topic/show?id=05fe2665508' target=_blank style='color:#2F92EE;'>#体能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26655, encryptionId=05fe2665508, topicName=体能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80ae38174281, createdName=liubm568, createdTime=Sat May 23 16:12:17 CST 2020, time=2020-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666023, encodeId=a4291666023c0, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Sat Oct 31 05:12:17 CST 2020, time=2020-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049286, encodeId=318e204928654, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Wed Mar 17 15:12:17 CST 2021, time=2021-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558187, encodeId=3075155818ef1, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Sat Apr 11 04:12:17 CST 2020, time=2020-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040708, encodeId=26c71040e082b, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Apr 09 16:12:17 CST 2020, time=2020-04-09, status=1, ipAttribution=)]
    2020-04-11 zsyan
  5. [GetPortalCommentsPageByObjectIdResponse(id=1770514, encodeId=f3021e7051415, content=<a href='/topic/show?id=05fe2665508' target=_blank style='color:#2F92EE;'>#体能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26655, encryptionId=05fe2665508, topicName=体能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80ae38174281, createdName=liubm568, createdTime=Sat May 23 16:12:17 CST 2020, time=2020-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666023, encodeId=a4291666023c0, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Sat Oct 31 05:12:17 CST 2020, time=2020-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049286, encodeId=318e204928654, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Wed Mar 17 15:12:17 CST 2021, time=2021-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558187, encodeId=3075155818ef1, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Sat Apr 11 04:12:17 CST 2020, time=2020-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040708, encodeId=26c71040e082b, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Apr 09 16:12:17 CST 2020, time=2020-04-09, status=1, ipAttribution=)]
    2020-04-09 misszhang

    前列腺癌相关研究,学习了,谢谢梅斯

    0

相关资讯

Sci Transl Med: 转移性前列腺癌新突破:免疫检查点抑制剂彰显成效!

德克萨斯大学安德森癌症中心进行的伊匹单抗Ⅱ期临床试验中,研究人员在一组患者的肿瘤中发现了存在活性T细胞反应的预处理证据,在接受伊匹单抗治疗后,患者的生存期明显延长。

经典病例:高危前列腺癌新辅助新型内分泌治疗+前列腺癌根治术

57岁男性,因“查体发现前列腺特异抗原(PSA)升高5天”于门诊就诊,否认既往疾病史。

​经典病例:高危mHSPC患者确诊之初即勇敢启用新型内分泌治疗,这个决定做对了!

76岁患者,主诉“进行性排尿困难2年余,加重1周”,于2019年4月29日就诊于本院。2年来无明显诱因出现排尿困难、尿线细而无力、射程短,未经系统检查治疗,之后逐渐加重。既往体健,余无殊。

Oncogene:p300/CBP抑制剂能够增强前列腺中程序性死亡配体1阻断治疗的效果

抗体药物的程序性死亡配体1(PD-L1)阻断在癌症治疗中是一种很有前景的治疗方法,而在许多类型癌症的临床响应,包括前列腺癌(PCa)仍旧有限。肿瘤细胞通过外泌体或者剪接变异分泌PD-L1,并且在许多类

Sci Rep:MicroRNA-299-3p的多元功能促进了抗肿瘤微环境的形成

前列腺癌(PCa)是世界范围内影响男性健康最常见的癌症之一。雄激素受体(AR)信号是PCa和PCa治疗的核心部分。而MicroRNAs(miRNAs)通过调节信号途径在前列腺癌的调控中具有关键的作用。

Nat Commun:OXPHOS在高等级前列腺癌中的重构参与了mtDNA变异并增加琥珀酸氧化

能量代谢的重组和线粒体的适应被认为影响了前列腺癌的发展和恶化。最近,有研究人员报道了良性/恶性人类前列腺组织样本中,线粒体呼吸、DNA变异和基因表达的情况。